<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000631495"><TermName>degarelix</TermName><TermPronunciation>(DEH-guh-REH-lix)</TermPronunciation><TermDefinition><DefinitionText>A drug that is used to treat advanced prostate cancer and is also being studied in the treatment 
of benign prostatic hyperplasia.  Degarelix binds to gonadotropin-releasing hormone (GnRH) 
receptors in the pituitary gland. This causes the body to stop making testosterone, which 
prostate cancer needs to grow. Degarelix is a type of GnRH antagonist. Also called Firmagon.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000722790" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;degarelix&quot;" language="en" id="_3"/><MediaLink ref="CDR0000722789" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;degarelix&quot;" language="es" id="_4"/><SpanishTermName>degarelix</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar el cáncer de próstata en estadio avanzado; también está en estudio para tratar la hiperplasia prostática benigna.  se une a los receptores de la hormona liberadora de gonadotropina (GnRH) de la glándula pituitaria. Esto hace que el cuerpo deje de elaborar testosterona que el cáncer de próstata necesita para crecer.  es un tipo de antagonista de la GnRH. También se llama Firmagon.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-01-27</DateFirstPublished><DateLastModified>2010-12-09</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000631480">Degarelix</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
